Pre-surgery combination therapy for intermediate liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving a combination of targeted therapy and immunotherapy before surgery can shrink liver tumors and improve outcomes in people with intermediate-stage liver cancer. The study uses a special computer model to see if you might benefit from this approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have not had any previous treatment (like surgery, chemotherapy, or radiation) for your liver cancer.
- Your liver function is good enough (Child-Pugh score 7 or below).
- You are able to do most daily activities on your own (ECOG score 0 or 1).
- An MRI shows your liver cancer is at an intermediate stage and can be safely removed with surgery.
- You are willing to have a biopsy to confirm the type of liver cancer before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment given before surgery for liver cancer that is at high risk of coming back. You would receive a combination of chemotherapy directly into the liver artery (HAIC), a targeted pill (lenvatinib), and an immunotherapy drug (a PD-1 inhibitor) — if a computer model predicts you might benefit.
This trial tests if combining three therapies (sintilimab, lenvatinib, and HAIC) before surgery can help shrink liver tumors that are on the borderline of being removable. It's for people whose cancer has spread into nearby blood vessels but not to other organs.
This trial compares two standard treatments (TACE and HAIC) when combined with an immunotherapy drug (PD-1 inhibitor) and an oral targeted therapy (lenvatinib) for people with liver cancer that cannot be surgically removed. The goal is to see which approach works better in shrinking tumors and improving outcomes.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests a triple combination of liver-directed chemotherapy (HAIC) plus immunotherapy (PD-1 inhibitor) and targeted therapy (Lenvatinib) for people with advanced liver cancer that has spread into the portal vein and who have already tried and failed standard treatments.
This trial tests a three-drug combination for a specific type of liver cancer called infiltrative hepatocellular carcinoma. It combines a liver-directed chemotherapy infusion (HAIC) with two oral and intravenous drugs (lenvatinib and a PD-1 inhibitor) to see if it works better than lenvatinib alone.
Hear when a new HCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.